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Summary
Background Mechanical chest compression devices have the potential to help maintain high-quality cardiopulmonary 
resuscitation (CPR), but despite their increasing use, little evidence exists for their eﬀ ectiveness. We aimed to study 
whether the introduction of LUCAS-2 mechanical CPR into front-line emergency response vehicles would improve 
survival from out-of-hospital cardiac arrest.
Methods The pre-hospital randomised assessment of a mechanical compression device in cardiac arrest (PARAMEDIC) 
trial was a pragmatic, cluster-randomised open-label trial including adults with non-traumatic, out-of-hospital cardiac 
arrest from four UK Ambulance Services (West Midlands, North East England, Wales, South Central). 91 urban and 
semi-urban ambulance stations were selected for participation. Clusters were ambulance service vehicles, which were 
randomly assigned (1:2) to LUCAS-2 or manual CPR. Patients received LUCAS-2 mechanical chest compression or 
manual chest compressions according to the ﬁ rst trial vehicle to arrive on scene. The primary outcome was survival at 
30 days following cardiac arrest and was analysed by intention to treat. Ambulance dispatch staﬀ  and those collecting 
the primary outcome were masked to treatment allocation. Masking of the ambulance staﬀ  who delivered the 
interventions and reported initial response to treatment was not possible. The study is registered with Current 
Controlled Trials, number ISRCTN08233942.
Findings We enrolled 4471 eligible patients (1652 assigned to the LUCAS-2 group, 2819 assigned to the control group) 
between April 15, 2010 and June 10, 2013. 985 (60%) patients in the LUCAS-2 group received mechanical chest compression, 
and 11 (<1%) patients in the control group received LUCAS-2. In the intention-to-treat analysis, 30 day survival was similar 
in the LUCAS-2 group (104 [6%] of 1652 patients) and in the manual CPR group (193 [7%] of 2819 patients; adjusted odds 
ratio [OR] 0·86, 95% CI 0·64–1·15). No serious adverse events were noted. Seven clinical adverse events were reported in 
the LUCAS-2 group (three patients with chest bruising, two with chest lacerations, and two with blood in mouth). 15 device 
incidents occurred during operational use. No adverse or serious adverse events were reported in the manual group.
Interpretation We noted no evidence of improvement in 30 day survival with LUCAS-2 compared with manual 
compressions. On the basis of ours and other recent randomised trials, widespread adoption of mechanical CPR 
devices for routine use does not improve survival. 
Funding National Institute for Health Research HTA – 07/37/69.
Copyright © Perkins et al. Open Access article distributed under the terms of CC BY.
Introduction
The burden of cardiac arrest out of hospital is 
substantial, with an estimated 424 000 cardiac arrests 
occurring each year of about in the USA1 and 275 000 in 
Europe.2 As few as one in 12 victims of cardiac arrest out 
of hospital survive to return home.3,4 High-quality chest 
compressions of suﬃ  cient depth5 and rate,6 with full 
recoil of the chest between compressions7 and avoidance 
of interruptions8 are crucial to survival. Maintenance 
of high-quality compressions during out-of-hospital 
resuscitation is diﬃ  cult because of the small number of 
crew present, fatigue, patient access, competing tasks 
(eg, deﬁ brillation, vascular access) and diﬃ  culty of 
performing resuscitation in a moving vehicle.9
Mechanical compression devices suitable for use in the 
pre-hospital environment have been developed to automate 
and potentially improve this process. At the time of 
initiating this study, one large randomised trial of a load 
distributing band mechanical device had been done and 
was terminated early because of the worsened long-term 
outcomes in patients allocated to mechanical compression.10 
The subsequent Cochrane review reported insuﬃ  cient 
evidence to conclude that mechanical chest compressions 
are associated with beneﬁ t or harm and their widespread 
use is not supported.11 Since then, two further large 
randomised eﬃ  cacy trials have been reported. The CIRC 
trial12 assessed the load distributing band and reported 
it was equivalent to manual cardiopulmonary resuscitation 
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(CPR). The LINC trial13 assessed the LUCAS device and 
concluded that mechanical CPR did not result in improved 
outcomes compared with manual CPR.13
Previous trials were designed as eﬃ  cacy (explanatory) 
trials, which aim to answer the question “Can this 
intervention work under ideal conditions?”. We sought to 
study mechanical CPR use under real life conditions, and 
therefore adopted a pragmatic design for the pre-hospital 
randomised assessment of a mechanical compression 
device in cardiac arrest (PARAMEDIC) trial. The trial 
sought to assess whether LUCAS-2 was better than 
manual CPR for the improvement of 30 day survival 
in adults receiving resuscitation for non-traumatic, 
out-of-hospital cardiac arrest.
Methods
Trial design and participants
The PARAMEDIC trial was a pragmatic, cluster 
randomised trial, with ambulance service vehicles as the 
unit of randomisation. The trial protocol has been 
published previously.14
The trial was done in partnership with four UK National 
Health Service (NHS) Ambulance Services (West Midlands, 
North East England, Wales, South Central). These sites 
serve a total population of 13 million people spread over 
62 160 km². We selected 91 ambulance stations for 
participation based on their location (urban and semi-urban 
settings, representing 25% of stations). A dispatch centre 
in each region coordinated the emergency response. The 
nearest available rapid response vehicle (RRV) or 
ambulance was dispatched to cases of suspected cardiac 
arrest. Back-up was provided by a second vehicle as soon as 
possible. If there was clear evidence that life was extinct (eg, 
rigor mortis, post-mortem staining; see appendix for full 
details) or the patient had a do-not-attempt-resuscitation 
order, ambulance staﬀ  were authorised to recognise death 
and withhold CPR. Where resuscitation was indicated, 
ambulance staﬀ  had been trained in advanced airway 
management, drug admin istration, and external deﬁ b-
rillation, and follow standardised national guidelines based 
on the European Resuscitation Council Guide lines.15,16 If 
the patient did not respond despite full ALS intervention 
and remained asystolic for more than 20 min then the 
resuscitation attempt could be discontinued. Unless these 
criteria were met, resuscitation was continued and the 
patient was transported to the nearest emergency 
department with continuous CPR. CPR quality and 
feedback technology was not available in any of the 
participating ambulance services.
We chose broad eligibility criteria, indicating the 
pragmatic nature of the trial. Individual patients were 
included in the study if a trial vehicle was the ﬁ rst 
ambulance service vehicle on scene, the patient was in 
cardiac arrest outside of a hospital, resuscitation was 
attempted, and the patient was known or believed to be 
aged 18 years or older. Exclusion criteria were cardiac 
arrest caused by trauma, and known or clinically 
apparent pregnancy.
Ambulance services recorded cardiac arrest data 
according to variables contained in the Utstein template.17 
Every ambulance service submitted these data to a central 
trial database.
Enrolment proceeded with a waiver of informed 
consent, in line with the Mental Capacity Act 2005. The 
trial team contacted patients who were discharged from 
hospital to let them know of their enrolment and to invite 
them to take part in the follow-up 3 months and 
12 months after cardiac arrest. Those willing to take part 
provided written informed consent. For those who did 
not have capacity, a personal consultee completed the 
questionnaires on behalf of the patient.
The Coventry Research Ethics Committee (reference 
09/H1210/69) approved the study, and University of 
Warwick, UK sponsored it. The study was done in 
accordance with the principles of Good Clinical Practice 
and the Mental Capacity Act (2005).
Randomisation and masking
Because the number of LUCAS devices available to the 
trial was limited to 143, we used a ratio of about 1 LUCAS 
to 2 control to optimise eﬃ  ciency. Individual ambulance 
See Online for appendix
Figure 1: Trial proﬁ le
*Seven met more than one exclusion criteria. †Reasons LUCAS-2 not used: 78 because of crew not trained; 
168 because of crew error; 26 no device in vehicle; 102 unsuitable patients (58 patient too large, 22 patient too 
small, 22 other reason–eg, chest deformity), 14 device issues, 140 not possible to use device; 110 reason unknown. 
Reasons for LUCAS-2 use in control group were crew error.
418 clusters recruited
11 171 patients from emergency 
incidents attended
4689 assessed for eligibility 
6482 recognition of life extinct or 
no resuscitation attempted
218 excluded*
2 pregnant
107 trauma
107 aged younger than 18 years
9 not out of hospital              4471 enrolled
147 clusters allocated to LUCAS-2 group
1652 patients allocated to LUCAS-2 group
985 received LUCAS-2 chest compression
638 received manual chest compression†
29 intervention received unknown
271 clusters allocated to control group
2819 patients allocated to control group
2808 received manual chest compression
11 received LUCAS-2 chest compression
1 unknown survival status
1652 followed up to 3 months and 12 months
 
1652 analysed
2818 followed up to 3 months and 12 months
2818 analysed
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vehicles (clusters) were assigned with a computer-
generated randomisation sequence, which stratiﬁ ed by 
station and vehicle type (ambulance or RRV).
Individual patients were allocated to the LUCAS-2 or 
control (standard manual chest compression) group 
according to the ﬁ rst trial vehicle on scene. We obtained 
information from ambulance services on all potential 
cardiac arrests attended by trial vehicles, and included 
all eligible patients in the trial, thereby minimising 
selection bias.
Ambulance dispatch staﬀ  were unaware of the 
randomised allocations. Masking of ambulance clinicians 
was not possible, since they gave the intervention. 
Vehicles randomly assigned to LUCAS-2 were identiﬁ ed 
to ambulance clinical staﬀ  at the start of the shift during 
vehicle checks and through stickers contained in the cab 
of the vehicle and on the outside of the vehicle. We 
extracted short-term outcomes from ambulance or 
hospital records. We obtained survival status at 30 days, 
3 months, and 12 months from the NHS Information 
Centre’s central death register. Trial staﬀ  who assessed 
patient neurological outcome were unaware of the 
randomised allocation or the treatment received.
Procedures
Paramedics seconded to work on the trial and clinical 
educator staﬀ  trained all operational ambulance staﬀ  to 
use LUCAS-2. Because of the vehicle movements and 
staﬀ  rotations, staﬀ  serviced vehicles that were randomly 
assigned to both LUCAS-2 and manual groups. Training 
was carefully designed by the ambulance services on the 
basis of the manufacturers guidance. Because of the 
pragmatic design of this trial, training was developed in 
accordance with the process by which new technology 
would be introduced in routine practice into NHS 
Ambulance Services. This preparation included access to 
online training resources and included 1–2 h face-to-face 
training, updated annually. Training covered the study 
protocol and procedures, how to operate the LUCAS-2 
device, and the importance of high-quality CPR. Training 
included hands-on device deployment practice, with a 
resus citation manikin, and emphasised the importance 
of rapid deployment with minimum interruptions in 
CPR. A competency checklist was completed before 
authorising staﬀ  to deploy the LUCAS-2 device. Research 
paramedics reviewed all cases and provided feedback to 
individual staﬀ  as required. The rate of device use and 
reasons for non-use were fed back to participating 
services on a quarterly basis.
LUCAS-2 (Physio-Control Inc/Jolife AB, Lund, Sweden) 
provides chest compressions between 40–53 mm in depth 
(according to patient size) at a rate of 102 min–¹ and 
ensures full chest recoil between compressions and an 
equal time in compression and decompression. In the 
LUCAS-2 group, staﬀ  initiated manual CPR and switched 
the device on. Once powered up manual compressions 
were paused brieﬂ y while the back plate was inserted. 
CPR was restarted while the central arms were positioned 
until locked in place, suction cup was deployed and device 
activated. After this procedure, ECG monitoring was 
For the online training 
resources see http://www.
warwick.ac.uk/go/paramedic
LUCAS-2 
(n=1652)
Manual CPR 
(n=2819)
Age, years (mean [SD]) 71·0 (16·3) 71·6 (16·1)
Male 1039 (63%) 1774 (63%)
Aetiology
Presumed cardiac 1417 (86%) 2445 (87%)
Respiratory 125 (8%) 191 (7%)
Submersion 5 (<1%) 7 (<1%)
Unknown 48 (3%) 74 (3%)
Other (non-cardiac) 57 (3%) 102 (4%)
Location
Home 1336 (81%) 2336 (83%)
Public place 225 (14%) 362 (13%)
Other 91 (6%) 121 (4%)
Witnessed cardiac arrest 1001 (61%) 1749 (62%)
Bystander 704 (43%) 1223 (43%)
EMS 250 (15%) 449 (16%)
Non-EMS health care 47 (3%) 75 (3%)
Not known 0 2 (<1%)
Bystander CPR before EMS arrival
CPR n (%) 716 (43%) 1238 (44%)
Not known 90 (5%) 168 (6%)
Median time from emergency call 
to vehicle arrival, min (IQR)
6·5 (4·8–9·1) 6·3 (4·6–9·2)
Initial rhythm
VF 364 (22%) 597 (21%)
VT 12 (1%) 18 (1%)
PEA 398 (24%) 707 (25%)
Asystole 824 (50%) 1384 (49%)
Not known 54 (3%) 113 (4%)
Deﬁ brillation before EMS arrival 19 (1%) 40 (2%)
Treatment of cardiac arrest
Intravenous drugs given 1366 (83%) 2255 (80%)
Not known 8 (<1%) 14 (<1%)
Intubation
Intubated 749 (45%) 1297 (46%)
Not known 33 (2%) 48 (2%)
LMA or supraglottic airway device
LMA or supraglottic airway device 
used
435 (26%) 736 (26%)
Not known 29 (2%) 47 (2%)
Transport to hospital 1099 (67%) 1868 (66%)
Transport to hospital status at 
handover
ROSC 377 (23%) 658 (23%)
CPR in progress 640 (39%) 1081 (38%)
Unknown 82 (5%) 129 (5%)
Data are n (%) or mean (SD). CPR=cardiopulmonary resuscitation. 
EMS=emergency medical services. VF=ventricular ﬁ brillation. VT=ventricular 
tachycardia. PEA=pulseless electrical activity. LMA=laryngeal mask airway. 
ROSC=return of spontaneous circulation.
Table 1: Baseline characteristics and treatment
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established and LUCAS-2 was brieﬂ y paused to check the 
ECG rhythm. If the patient was in a shockable rhythm 
LUCAS-2 was restarted and deﬁ brillation was attempted 
with continuous mechanical CPR.
Patients in the control group received manual CPR 
aiming for a target compression depth of 50–60 mm, 
rate 100–120 min–¹, full recoil between compressions 
and an equal time in compression and decompression 
in line with guidelines. CPR was started on arrival and 
ECG monitoring established. Chest compressions were 
paused brieﬂ y to allow rhythm analysis and if 
appropriate, attempted deﬁ brillation. Both groups 
received compression to ventilation ratio of 30:2 before 
intubation and continuous compressions with asyn-
chronous ventilation after intubation.
Outcomes
The primary outcome of the study was survival to 30 days 
after the cardiac arrest event. The main secondary clinical 
outcomes were survived event (return of spontaneous 
circulation [ROSC] sustained until admission and 
transfer of care to medical staﬀ  at the receiving hospital), 
survival to 3 months, survival to 12 months, and survival 
with favourable neurological outcome at 3 months. The 
initial trial protocol originally speciﬁ ed survival to 
hospital discharge as an additional outcome; this 
outcome is not reported here because survival to 30 days 
is more clinically meaningful, and these data could not 
be obtained from all hospitals included in the trial 
because of logistical and governance diﬃ  culties. We have 
reported ROSC as an additional (non-prespeciﬁ ed) 
outcome since it is part of the Utstein template.17
We deﬁ ned favourable neurological outcome as a 
Cerebral Performance Category (CPC) score17 of 1 or 2 at 
3 months. CPC was extracted from medical records or 
assessed at a face-to-face visit done by research staﬀ .
Statistical analysis
At the time of the design of this study, there were no 
randomised trials using the LUCAS device on which to 
base the likely treatment eﬀ ect. We determined the 
minimally important diﬀ erence to our decision makers 
(the NHS) through discussion with partner ambulance 
services and subsequent agreement with the funder. The 
study had 80% power to ﬁ nd a signiﬁ cant result (with 
threshold two-sided p value of 0·05) if the incidence of 
survival to 30 days was 5% in the manual CPR group and 
7·5% in the LUCAS-2 group. Using an intracluster 
correlation coeﬃ  cient of 0·01 to allow for clustering, and 
a cluster size of 15, we aimed to recruit 245 clusters 
(3675 patients) into the trial.
The target sample size was revised in September, 2012, 
after recruitment of 2469 patients, to take account of the 
frequency of use of LUCAS-2 and updated information 
on the cluster size. With the agreement of the Data 
Monitoring Committee and the Trial Steering Committee, 
we increased the target sample size to 4344 patients. We 
estimated this sample size to have a suﬃ  cient number of 
cases of LUCAS-2 use to maintain the originally speciﬁ ed 
power. The sample size re-estimation did not use any 
information from comparisons between the trial groups.
The primary analysis was by intention to treat. This 
analysis explores if the treatment works under the usual 
conditions, with all the noise inherent therein. We used 
complier average causal eﬀ ect (CACE) analyses, to 
estimate the eﬀ ect in cardiac arrest where the protocol was 
followed.18,19 CACE estimates the treatment eﬀ ect in people 
randomly assigned to the intervention who actually 
received it, by comparing compliers in the intervention 
group with those participants in the control group who 
would have been compliers if they had been allocated 
to the intervention group. This analysis retains the 
advantages of randomisation and avoids introducing bias, 
hence CACE is preferred to per-protocol analysis. We did 
two CACE analyses, deﬁ ning compliers in diﬀ erent ways. 
In CACE1, we treated as non-compliant those cases in 
which LUCAS-2 was not used for unknown or trial-related 
reasons that would not occur in real-life clinical practice 
(eg, crew were not trained in trial procedures, crew 
misunderstood the trial protocol, the device was missing 
from the vehicle). This analysis omits trial-related non-use 
and might be a better estimate of the treatment eﬀ ect in 
real-world clinical practice analysis by intention to treat. In 
the CACE2 analysis, we only treated as compliant those 
LUCAS-2 
(n=1652)
Control 
(n=2819)
Unadjusted OR 
(95% CI)
Adjusted OR 
(95% CI)
Survival to 30 days
Survived to 30 days 104 (6%) 193 (7%) 0·91 (0·71–1·17) 0·86 (0·64–1·15)
Not known 0 1 (<1%) ·· ··
ROSC
ROSC 522 (32%) 885 (31%) 1·02 (0·89–1·16) 0·99 (0·86–1·14)
Not known 58 (4%) 82 (3%) ·· ··
Survived event
Survived event 377 (23%) 658 (23%) 0·97 (0·83–1·14) 0·97 (0·82–1·14)
Not known 82 (5%) 129 (5%) ·· ··
Survival to 3 months
Survived to 3 months 96 (6%) 182 (6%) 0·89 (0·69–1·15) 0·83 (0·61–1·12)
Not known 0 1 (<1%) ·· ··
Survival to 12 months 89 (5%) 175 (6%) 0·86 (0·60–1·12) 0·83 (0·62–1·11)
Survival with favourable 
neurological outcome (CPC 1–2)
77 (5%) 168 (6%) 0·77 (0·59–1·02) 0·72 (0·52–0·99)
CPC ·· ··
1 67 (4%) 153 (5%) ·· ··
2 10 (1%) 15 (1%) ·· ··
3 14 (1%) 10 (<!%) ·· ··
4 2 (<1%) 1 (<1%) ·· ··
5 1556 (94%) 2636 (94%) ·· ··
Not known 3 (<1%) 4 (<1%) ·· ··
Data are n (%) unless otherwise indicated. OR=odds ratio. ROSC=return of spontaneous circulation. CPC=cerebral 
performance category score.
Table 2: Outcomes
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cases in which LUCAS-2 was actually used, and this 
analysis therefore estimates eﬃ  cacy—ie, the treatment 
eﬀ ect in patients who received LUCAS-2.
For intention-to-treat analyses, we used ﬁ xed-eﬀ ect 
logistic regression models to obtain unadjusted and 
adjusted odds ratios (ORs) and 95% CIs. The prespeciﬁ ed 
covariates used in the adjusted models were age, sex, 
response time, bystander CPR, and initial rhythm. We 
attempted adjusting for the clustering design using 
multilevel logistic models (using the GLIMMIX 
procedure with logit link function based on the binomial 
distribution). Because of the extremely low survival rates 
in each cluster (vehicle), the multilevel models could not 
be ﬁ tted with the vehicle random eﬀ ect since this eﬀ ect 
was not estimable. For this reason, we assumed that the 
intracluster correlation coeﬃ  cient was negligible (0·001) 
and ordinary logistic regressions were ﬁ tted. We also did 
prespeciﬁ ed subgroup analyses, by: (1) initial rhythm 
(shockable vs non-shockable); (2) cardiac arrest witnessed 
versus not witnessed; (3) type of vehicle (RRV versus 
ambulance); (4) bystander CPR versus no bystander CPR; 
(5) region, and (6) aetiology (presumed cardiac, or 
non-cardiac); (7) age and (8) response time. We ﬁ tted 
logistic regression models for the primary outcome 
measure with the inclusion of an interaction term to 
examine whether the treatment eﬀ ect diﬀ ered between 
the subgroups. Age and response times are continuous 
variables and we assessed these using multivariate 
fractional polynomials.
We did all analyses using Statistical Analysis Software 
(SAS) version 9·3 ( SAS Institute, Marlow, UK). This 
trial is registered on the International Standard 
Randomised Controlled Trial Number Register, number 
ISRCTN08233942.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. RL had full access to all data in the study. GDP 
and SG had ﬁ nal responsibility for the decision to 
submit for publication.
Results
We recruited 418 emergency vehicles (287 dual-manned 
ambulances and 131 single-manned rapid response 
vehicles) and randomly assigned them to either the 
LUCAS-2 group (147 clusters) or the control group 
(271 clusters; ratio 1:1·8; ﬁ gure 1). In the 3 years of the 
study, individual ambulance staﬀ  attended on average 
4·1 (3·6) arrests in the control group and 3·0 (2·3) in 
the LUCAS group.
The trial ran between April 15, 2010, and June 10, 2013 
(with a 12 months’ follow-up) during which time trial 
vehicles attended 11 171 emergency incidents (ﬁ gure 1). 
The trial ﬁ nished when the revised target sample size 
was exceeded. Cardiac arrest was conﬁ rmed and 
resuscitation attempted in 4689 cases of which 218 cases 
were ineligible and excluded. The proportion of arrests 
for which resuscitation was attempted did not diﬀ er 
between groups (1737 [41%] of 4192 for the LUCAS-2 
group; 2953 [42%] of 6980 for the control group).
4471 patients were enrolled in the study. 985 (60%) of 
the 1652 patients in the LUCAS-2 group received 
mechanical chest compression. The reasons for non-use 
of LUCAS-2 were trial related (n=272), not possible 
(n=256), or unknown (n=110; ﬁ gure 1). We did not note 
any major imbalances in baseline characteristics between 
the trial groups (table 1). One patient in the control group 
was lost to follow-up. No patient requested to withdraw 
their data from the study.
For the primary outcome, 30 day survival was similar 
in the LUCAS-2 and control groups (104 [6%] of patients 
in the LUCAS-2 group, 193 [7%] of patients in the control 
group, adjusted OR 0·86 [95% CI 0·64–1·15]; table 2)
The proportion of patients achieving any ROSC and 
sustained ROSC with spontaneous circulation until 
admission and transfer of care to the medical staﬀ  at the 
receiving hospital (survived event) was very similar in 
the two groups (table 2). Survival at 3 months was also 
similar to the primary outcome, indicating that little 
mortality occurs between 30 days and 3 months.
The number of patients with a favourable neurological 
outcome (CPC 1 or 2) was lower in the LUCAS-2 group 
than in the control group (table 2).
Both CACE analyses had similar results to those of 
the intention-to-treat analysis and are presented in 
table 3. LUCAS-2 had almost no eﬀ ect on ROSC and 
survival of event, and 30 day survival did not diﬀ er 
between groups. The ORs for 30 day survival were 
similar to those for the intention-to-treat analysis, but 
the 95% CIs were slightly wider (table 2). However, 
survival with CPC1-2 was lower in the LUCAS-2 group 
CACE 1 CACE 2
LUCAS-2 Control OR (95% CI) LUCAS-2 Control OR (95% CI)
Survival to 30 days 81/1241 (7%) 153/2155 (7%) 0·92 (0·69–1·21) 50/985 (5%) 99/1710 (6%) 0·87 (0·61–1·23)
CPC 1–2 62/1238 (5%) 142/2151 (7%) 0·76 (0·56–1·03) 38/983 (4%) 101/1701 (6%) 0·65 (0·45–0·96)
Survived event 297/1241 (24%) 537/2026 (27%) 0·90 (0·77–1·06) 232/985 (24%) 415/1704 (24%) 0·97 (0·81–1·16)
ROSC 410/1212 (34%) 702/2104 (33%) 1·01 (0·88–1·17) 318/971 (33%) 538/1680 (32%) 1·02 (0·87–1·19)
CPC=cerebral performance category score. ROSC=return of spontaneous circulation. CACE=complier average causal eﬀ ect.
Table 3: CACE analyses
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than in the control group in both CACE analyses. 
The appendix includes patient characteristics for the 
CACE analyses.
Subgroup analyses according to whether the arrest was 
witnessed, type of vehicle (ambulance or solo responder 
car), whether the patient received bystander CPR, 
aetiology, and region showed no signiﬁ cant diﬀ erence in 
30 day survival between the subgroups (table 4). 
The subgroup analysis by initial rhythm showed a 
diﬀ erence in treatment eﬀ ect between patients with a 
shockable initial rhythm and those with PEA or 
asystole; survival was lower in the LUCAS-2 group in 
those with shockable initial rhythms than in the 
control group.
Seven clinical adverse events were reported in the 
LUCAS-2 group (three events of chest bruising, two of 
chest laceration, and two of blood in mouth). No serious 
adverse events were reported. 15 device incidents 
occurred during operational use (four incidents in 
which alarms sounded, seven in which the device 
stopped working, and four other device incidents). No 
adverse or serious adverse events were reported in the 
control group.
Discussion
In this pragmatic, cluster randomised trial, the 
introduction of LUCAS-2 did not improve the primary 
outcome of survival to 30 days. Meta-analysis of the 
present study’s ﬁ ndings alongside the results of the 
two previous randomised trials including the LUCAS 
mechanical CPR device showed no evidence of 
superiority in 30 day survival, survival to discharge, or 
neurological function at 3 months (panel, ﬁ gure 2).
This study was designed to assess the eﬀ ectiveness of 
LUCAS-2 when implemented in a real life setting. As 
such it diﬀ ered from recent industry sponsored eﬃ  cacy 
LUCAS-2 Control OR (95% CI)
Initial rhythm
VF or VT 69/376 (18%) 148/615 (24%) 0·71 (0·52–0·98)*
PEA or asystole 24/1222 (2%) 30/2090 (1%) 1·38 (0·80–2·36)
Rhythm not 
known
54 113 ··
Witnessed status
Witnessed 89/1001 (9%) 163/1749 (9%) 0·96 (0·73–1·25)
Not witnessed 10/528 (2%) 21/864 (2%) 0·78 (0·36–1·66)
Witnessed status 
not known
123 205 ··
Bystander CPR
Given 42/716 (6%) 68/1238 (5%) 1·07 (0·72–1·59)
Not given 59/846 (7%) 115/1413 (8%) 0·86 (0·61–1·17)
Not known 90 167 ··
Type of vehicle
Ambulance 60/1063 (6%) 127/1773 (8%) 0·78 (0·56–1·06)
Rapid response 
car
44/589 (7%) 66/1045 (6%) 1·20 (0·81–1·78)
Region
A 16/186 (9%) 23/357 (6%) 1·37 (0·70–2·66)
B 9/148 (6%) 33/359 (9%) 0·64 (0·30–1·37)
C 19/346 (5%) 22/352 (6%) 0·87 (0·46–1·64)
D 60/972 (6%) 115/1750 (7%) 0·94 (0·68–1·29)
Aetiology
Presumed 
cardiac
91/1417 (6%) 173/2445 (7%) 0·90 (0·69–1·17)
Other 9/130 (7%) 7/198 (4%) 2·03 (0·74–5·59)
Data are n/N (%) unless otherwise indicated. VT=ventricular tachycardia. 
PEA=pulseless electrical activity. CPR=cardiopulmonary resuscitation. 
VF=ventricular ﬁ brillation. *Interaction eﬀ ect of subgroup p<0·05. 
Table 4: Subgroup analyses for primary outcome (30 day survival)
Panel: Research in context
Systematic review
We searched PubMed and The Cochrane Library from 2002, 
to September, 2014, for randomised trials assessing LUCAS 
for out of hospital cardiac arrest, using a combination of text 
(LUCAS, LUCAS-2, cardiac arrest, mechanical chest 
compression, mechanical CPR) and medical subject headings 
terms (out-of-hospital cardiac arrest; death, sudden, cardiac; 
heart arrest). We identiﬁ ed two randomised trials: LINC,13 
which was sponsored by the manufacturer of LUCAS and 
recruited 2593 patients, and a much smaller pilot study20 
done by the same investigators. We assessed bias risk of the 
trials using the Cochrane risk of bias method. Both of the 
included trials were at low risk of bias for randomisation 
methods, completeness of data, and selective reporting. 
Masking of clinicians, participants, and outcome assessment 
was not possible, but mortality and CPC score were very 
unlikely to have been inﬂ uenced by knowledge of trial 
allocations. We noted some important diﬀ erences between 
LINC and PARAMEDIC. First, the intervention assessed in 
LINC was a new treatment algorithm including mechanical 
chest compression, whereas in PARAMEDIC, mechanical 
chest compression was simply used to replace manual chest 
compression. Second, survivors in LINC were treated with 
hypothermia, whereas in PARAMEDIC post-resuscitation care 
was given according to hospitals’ usual practice.
Interpretation
Meta-analysis of the outcomes survived event and survival to 
hospital discharge or 30 days showed no evidence of 
inconsistency between the three trials’ results, and no evidence 
of improvement with LUCAS (survived event odds ratio [OR] 
1·00, 95% CI 0·90–1·11; survival OR 0·96, 0·80–1·15). The 
two trials that reported survival with CPC 1–2 had inconsistent 
results (I²=69%), but overall did not suggest that outcomes 
were better with LUCAS than with manual chest compression 
(random eﬀ ects model OR 0·93, 0·64–1·33). The reasons for 
the inconsistency are unclear, but could be related to the 
diﬀ erences between the trials, particularly in relation to the 
implementation strategies adopted. PARAMEDIC supports the 
ﬁ nding from LINC that use of LUCAS does not lead to an 
improvement in survival, but additionally found that 
neurological outcomes might be worse.
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trials12,13 which included more intensive initial and 
re- training, a run-in period; and in one study,12 a 
statistical inclusion phase whereby patients were 
excluded from analysis if quality of implementation fell 
below a predeﬁ ned threshold. Our pragmatic approach 
to training, developed by experienced ambulance 
training staﬀ , portrayed the training that would be 
delivered when rolling out new technology across UK 
ambulance services. In this setting, the average 
ambulance paramedic only encounters one to two cardiac 
arrests annually21 and CPR update training is provided 
annually, so it is unlikely that individuals became expert 
in the use of the device.
The success of implementation is particularly 
important when balancing the beneﬁ t versus harm 
potential for mechanical chest compression devices 
since interruptions in CPR and delays in device 
deployment are a major factor that can impact 
outcomes.22 In the present study 985 (60%) of 
1652 patients randomly assigned to LUCAS received the 
allocated intervention. While some cases of non-use 
were due to patient-related and device-related factors, a 
proportion (15%) arose because of diﬃ  culties inherent 
with implementation of new equipment and the 
training and quality issues associated with this. Another 
key diﬀ erence between our study and other recent trials 
was the absence of CPR feedback technology in the 
participating ambulance services. CPR feedback devices 
allow the measurement and adjustment of CPR quality 
at the bedside.23 Although international guidelines 
published in 201024 suggested the devices could be 
considered as part of an overall strategy to improve CPR 
quality, their adoption into clinical practice has been 
variable. The scarcity of this technology limited our 
ability to report on the quality of CPR and monitor the 
performance of our implementation strategy. These 
ﬁ ndings serve to highlight the potential limitations of 
expecting the ﬁ ndings from eﬃ  cacy trials to translate to 
real life practice without applying the same degree of 
rigor, attention and assessment applied during the 
index trials.
The sample size was increased to maintain the power 
of the study on the basis of the rate at which the 
intervention was used in practice. The intention-to-treat 
Figure 2: Meta-analysis of the outcomes survived event and survival to hospital discharge or 30 days 
(A) Survival to discharge or 30 days. (B) Survived event. (C) Survival with CPC 1–2.
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analysis provides the answer to our primary question of 
the eﬀ ectiveness of implementation of mechanical CPR 
into routine clinical practice. The two CACE analyses 
estimate the treatment eﬀ ect of LUCAS in participants 
who were compliant with the trial protocol, and those 
where LUCAS was actually used. Since this approach 
retains the initial randomised assignment, it overcomes 
the issues related to per-protocol and on-treatment 
analyses. These analyses served to conﬁ rm the direction 
of ﬁ ndings from the intention-to-treat analysis.
The ﬁ ndings of marginally worse neurological outcomes 
and lower survival in patients presenting with an initially 
shockable rhythm was unexpected. Although these 
analyses were deﬁ ned a priori, they were not the primary 
objective of the trial and should be interpreted with 
caution and deemed as hypothesis generating. One of 
these hypotheses is that interruptions in CPR during 
device deployment could cause reduced cardiac and 
cerebral perfusion. Alternatively, slightly more patients 
received adrenaline after randomisation in the LUCAS 
group than in the control group, which might increase 
cardiac instability and impair cerebral microcirculation.25 
Finally, deployment of LUCAS before the ﬁ rst shock is 
likely to have led to a delay in the time to ﬁ rst shock, which 
might in itself reduce survival.26
We chose to use a cluster randomised design with 
vehicles as the unit of randomisation. This design 
allowed us to include all cardiac arrests where a trial 
vehicle was ﬁ rst on scene, because recruitment to the 
trial was not dependent on a paramedic making a 
decision to randomise. This means that one of the major 
potential drawbacks of cluster randomisation, selection 
bias, was avoided because we have included in the trial 
all of the eligible patients. It is possible that selection 
bias could be introduced by paramedics having a lower 
threshold for initiation of resuscitation, in view of the 
knowledge that a LUCAS device was present. The 
independent data monitoring committee monitored this 
throughout the trial, by looking at the proportions of 
patients resuscitated when LUCAS and control vehicles 
were ﬁ rst on scene, and the characteristics of patients 
recruited to the two trial groups. No evidence of diﬀ erent 
resuscitation thres holds was found.
The implementation process was tailored to reﬂ ect 
how such technology would be implemented in the 
NHS and the study ﬁ ndings should be considered in 
that context. Health-care systems will need to consider 
carefully the ﬁ ndings from this and previous studies 
when considering the role of mechanical CPR during 
out-of-hospital cardiac arrest. Deployment across entire 
services will require substantial capital investment. This 
investment must be balanced against the accepted role 
such devices will continue to have when manual CPR is 
impractical or increased risk (eg, in a moving 
ambulance). Where organisations decide to adopt 
mechanical CPR it seems essential that suﬃ  cient 
resources are made available to support initial and 
regular refresher training and ongoing quality 
assurance. Future research should look to deﬁ ne the 
optimum method and frequency of such training.
In conclusion, this trial was unable to show any 
superiority of mechanical CPR and highlights the 
diﬃ  culties of training and implementation in real world 
EMS systems.
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